56 related articles for article (PubMed ID: 21663510)
41. Chronic Myeloid Leukemia--Prognostic Value of Mutations.
Kaleem B; Shahab S; Ahmed N; Shamsi TS
Asian Pac J Cancer Prev; 2015; 16(17):7415-23. PubMed ID: 26625737
[TBL] [Abstract][Full Text] [Related]
42. Can we afford to let sleeping dogs lie?
Deininger MW; Holyoake TL
Blood; 2005 Mar; 105(5):1840-1. PubMed ID: 15747396
[TBL] [Abstract][Full Text] [Related]
43. Why doesn't imatinib cure chronic myeloid leukemia?
Redner RL
Oncologist; 2010; 15(2):182-6. PubMed ID: 20124443
[TBL] [Abstract][Full Text] [Related]
44. Chronic myeloid leukaemia: the evolution of gene-targeted therapy.
Joske DJ
Med J Aust; 2008 Sep; 189(5):277-82. PubMed ID: 18759727
[TBL] [Abstract][Full Text] [Related]
45. Chronic myeloid leukemia-still a few questions.
Goldman JM
Exp Hematol; 2004 Jan; 32(1):2-10. PubMed ID: 14725895
[TBL] [Abstract][Full Text] [Related]
46. The development of imatinib as a therapeutic agent for chronic myeloid leukemia.
Deininger M; Buchdunger E; Druker BJ
Blood; 2005 Apr; 105(7):2640-53. PubMed ID: 15618470
[TBL] [Abstract][Full Text] [Related]
47. Chronic myeloid leukemia: mechanisms of resistance and treatment.
Jabbour E; Parikh SA; Kantarjian H; Cortes J
Hematol Oncol Clin North Am; 2011 Oct; 25(5):981-95, v. PubMed ID: 22054730
[TBL] [Abstract][Full Text] [Related]
48. Targeting oncogene dependence and resistance.
Hingorani SR; Tuveson DA
Cancer Cell; 2003 May; 3(5):414-7. PubMed ID: 12781357
[TBL] [Abstract][Full Text] [Related]
49. [Current state and the future of molecular target drugs: lessons learned from the success of imatinib].
Yamada H
Nihon Yakurigaku Zasshi; 2008 Dec; 132(6):339-42. PubMed ID: 19075528
[No Abstract] [Full Text] [Related]
50. New therapeutic approaches and prognostic factors in chronic myeloid leukemia.
Saglio G; Ulisciani S; Bosa M; Cilloni D; Rege-Cambrin G
Leuk Lymphoma; 2008 Apr; 49(4):625-8. PubMed ID: 18398722
[TBL] [Abstract][Full Text] [Related]
51. Tissue-Predisposition to Cancer Driver Mutations.
Peters L; Venkatachalam A; Ben-Neriah Y
Cells; 2024 Jan; 13(2):. PubMed ID: 38247798
[TBL] [Abstract][Full Text] [Related]
52. Clinical outcome of chronic myeloid leukemia imatinib-resistant patients: do BCR-ABL kinase domain mutations affect patient survival? First multicenter Argentinean study.
Bengió RM; Riva ME; Moiraghi B; Lanari E; Milone J; Ventriglia V; Bullorsky E; Tezanos Pinto Md; Murro H; Bianchini M; Larripa I
Leuk Lymphoma; 2011 Sep; 52(9):1720-6. PubMed ID: 21663510
[TBL] [Abstract][Full Text] [Related]
53. Monitoring minimal residual disease in BCR-ABL-positive chronic myeloid leukemia in the imatinib era.
Goldman J
Curr Opin Hematol; 2005 Jan; 12(1):33-9. PubMed ID: 15604889
[TBL] [Abstract][Full Text] [Related]
54. Resistance in the land of molecular cancer therapeutics.
Shannon KM
Cancer Cell; 2002 Aug; 2(2):99-102. PubMed ID: 12204529
[TBL] [Abstract][Full Text] [Related]
55. Targeted chronic myeloid leukemia therapy: Seeking a cure.
Fausel C
Am J Health Syst Pharm; 2007 Dec; 64(24 Suppl 15):S9-15. PubMed ID: 18056932
[TBL] [Abstract][Full Text] [Related]
56. Impact of BCR-ABL mutations on patients with chronic myeloid leukemia.
Hochhaus A; La Rosée P; Müller MC; Ernst T; Cross NC
Cell Cycle; 2011 Jan; 10(2):250-60. PubMed ID: 21220945
[TBL] [Abstract][Full Text] [Related]
[Previous] [New Search]
